“Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights:
- Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
- Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
- Commercially Available Cancer Immunotherapies: > 120
- Cancer Vaccines Market Opportunity: > US$ 20 Billion
- Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
- Marketed Cancer Monoclonal Antibodies’: > 70 mAbs
- Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts
- Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class
Download Report: https://www.kuickresearch.com/report-global-cancer-immunotherapy-market-opportunity,-dosage,-price-and-clinical-trials-insight-2026.php
Multiple treatment and therapeutic regimens for the cancer patients are being followed by the researchers across the globe in order to arrive with a suitable and reliable treatment for cancer patients. One line for the cancer treatments that has been discovered till now describes the potential and wide applications of the available treatments, but the discovery of immunotherapy in pharmaceutical industry has led to a complete phase transformation in a short period of time. The approach that the therapy can perform has led to the blind following of the therapy for the treatment of the cancer patients as well as increased research activities for the same. The increase in research activity of the therapy has led to development of several underlined therapies that are committed to provide high five -year overall survival rate.
In the past few years, the unending research and applications of immunotherapy for the cancer patients has made the market emerge as a novel opportunity for the generation of huge revenue by the pharmaceutical companies. In addition to this, the therapies available in the market are also capable of diminishing the adverse side effects that are associated with the other therapies. The failures that are associated with the other conventional therapies have also led to the advancement and huge demand for immunotherapies. Moreover, the increasing number of drugs available under the therapy for different cancers including solid cancer is estimated to poise the market towards huge appreciation and acceptance by the global researchers, clinicians, physicians and more specifically by the patients.
Among all the commercially available therapies that are available under immunotherapy, immune checkpoint inhibitors and monoclonal antibodies are widely used for the treatment of the cancer patients globally. Introduction of novel mechanisms of involving immune system for the healthcare benefits of the cancer patients is making the patients respond well to the market. Several different therapies and their drugs under clinical pipeline are estimated to deliver novel breakthroughs in the pharmaceutical market, thus making the novel therapy a tough competition in the cancer therapeutics industry.
As per the analysis conducted for the market of cancer immunotherapy at global level, it is estimated that increasing prevalence of the cancer cases and increasing failure rate of other commercial therapies are all contributing to the growing use of cancer immunotherapies for the treatment facility. The increased applications of the immunotherapy treatment for the cancer patients has also led to increased spending on the research activity, leading to stronger and more robust clinical pipeline such as of NK therapy and AIM therapy. It is believed the market has the potential to alter the unregulated and unstructured market of cancer therapeutics into a regulated one, marking the therapy as a door for several ground-breaking treatment prospects and exciting novel research frontiers.
Contact
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366
Table of Contents
- Immunotherapy for Cancer
1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy
- Types of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
- Dynamics of Global Cancer Immunotherapy Landscape
3.1 Favorable Developmental & Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon
- Cancer Vaccines: Transforming The Immunotherapy Landscape
4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines
- Monoclonal Antibodies: New Era of Immunotherapy
5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies
- Trails of T-Cell Therapies
6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy
- Application of Immune Checkpoint Inhibitors in Immunotherapy
7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors
- Role of Immunomodulators in Cancer Immunotherapy
8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators
- Development of Oncolytic Viral Immunotherapy
9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses
- Cytokines & Cancer Immunotherapy
10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines
- Interferons in Immunotherapy
11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons
- Interleukins in Immunotherapy
12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins
- GM-CSF in Immunotherapy
13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF
- Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product
- Cancer Immunotherapy Pipeline Overview
15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment
- Cancer Immune Check Point Inhibitors – Availability, Price, Dosage & Sales Analysis
16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)
- Cancer Monclonal Antibody Market – Availability, Price, Dosage & Sales Analysis
17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)
- Bispecific Antibody Market – Availability, Price, Dosage & Sales Analysis
18.1 Blincyto (Blinatumomab)
- Cancer Vaccine Market – Availability, Price, Dosage & Sales Analysis
19.1 Gardasil & Gardasil 9
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC
- Cancer Cytokines Drugs Market – Availability, Price, Dosage & Sales Analysis
20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)
- Oncolytic Virus Market – Availability, Dosage, & Price Analysis
21.1 Imlygic
- CAR-T Cell Therapy – Availability, Dosage, Price & Sales Analysis
22.1 Kymriah
22.2 Yescarta
- Marketed Cancer Cell Therapies Drugs
23.1 T-Lymphocyte Cell Therapy(Immuncell-LC®)
23.2 Zalmoxis
23.3 APCEDEN For RCC
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai Jia Fu Medical
- Marketed Cancer Cytokines Drugs
24.1 Aldesleukin (Proleukin®)
24.2 Denileukin Diftitox (ONTAK®)
24.3 Interferon Alpha (Multiferon®)
24.4 Interferon Alpha-2a (Roferon-A®)
24.5 Interferon Alpha-2a (Veldona®)
24.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
24.7 Interferon Alpha-2b(Intron® A)
24.8 Interferon Alpha-2b Biosimilar(Bioferon™)
24.9 Interferon Alpha-2b Biosimilar (Intalfa®)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeron®)
24.12 Interferon-Alpha-n3 (Alferon N®)
24.13 Interferon-Beta-1b (Feron®)
24.14 Interferon-Gamma (Ogamma®)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunace™)
- Marketed Cancer Vaccines
25.1 Bladder Cancer Vaccine (PACIS®)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC 001
25.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
25.7 Immuvac / Cadi 05
25.8 Immucyst / TheraCys
25.9 Melanoma Vaccine (MVax®)
25.10 Melanoma Vaccine (Melacine®)
25.11 Racotumomab (Vaxira®)
25.12 Reniale
25.13 Sipuleucel-T (Provenge®)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophage®)
- Marketed Cancer Monoclonal Antibodies
26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others
- Global Cancer Immunotherapy Market Future Prospects
- Competitive Landscape
28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics